<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174731</url>
  </required_header>
  <id_info>
    <org_study_id>D5740C00002</org_study_id>
    <nct_id>NCT02174731</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to
      epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, open-label, active-controlled study to evaluate
      the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in
      dialysis patients. Patients on hemodialysis (HD) or peritoneal dialysis (PD) who have been
      treated with an erythropoietin analogue or have an indication for treatment with an
      erythropoietin analogue will be evaluated for eligibility and randomized at a 1:1 ratio to
      treatment with roxadustat (with discontinuation of prior erythropoietin analogue therapy) or
      to an active-control group treated with epoetin alfa
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">September 26, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52</measure>
    <time_frame>Baseline (Day 1, Week 0), Week 28 to 52</time_frame>
    <description>Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation Analysis of Covariance (ANCOVA). Baseline Hb was used as a covariate and treatment group, cardiovascular (CV) history, geographic region and dialysis duration as fixed effects. The adjusted least squares (LS) mean estimates of change from baseline during Week 28 to Week 52 are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8‑Week Evaluation Period</measure>
    <time_frame>Baseline (Day 1, Week 0), Week 28 to 36</time_frame>
    <description>Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 36,without having received rescue therapy within 6 weeks prior to and during this 8 week evaluation period was analysed using Mixed Model of Repeated Measures (MMRM). Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 36 are presented for participants that did not receive rescue therapy within 6 weeks prior to and during this 8‑week evaluation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Total Time of Hb Within the Interval of &gt;=10 g/dL From Week 28 to Week 52</measure>
    <time_frame>Week 28 to 52</time_frame>
    <description>The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was &gt;=10 g/dL was computed and subsequently divided by the time between the measurements from Week 28 to Week 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52</measure>
    <time_frame>Week 28 to 52</time_frame>
    <description>The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was within 10-12 g/dL was computed and subsequently divided by the time between the measurement from Week 28 to 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24</measure>
    <time_frame>Baseline (Day 1, Week 0) to Week 24</time_frame>
    <description>Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analysed using ANCOVA. Baseline Hb and baseline LDL were used as covariates and treatment groups, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)</measure>
    <time_frame>Baseline (Day 1, Week 0), Week 28 to 52</time_frame>
    <description>Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb is defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Changes in Hb from baseline to mean value during Weeks 28 to 52 in participants with baseline hsCRP &gt;ULN was analyzed using a MAR based multiple imputation ANCOVA. Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 52 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)</measure>
    <time_frame>Week 36 to EOS (4 weeks after the treatment period)</time_frame>
    <description>Oral iron supplementation was allowed for both treatment groups without restriction. Oral iron was recommended for dietary supplementation to support erythropoiesis and as the first line treatment for prevention and treatment of iron deficiency, unless the participant was intolerant to this route of treatment. In participants receiving roxadustat, the Investigator was allowed to initiate the use of an approved IV iron supplement if a participant's Hb value had not sufficiently responded to 2 or more dose increases of the IP, and ferritin &lt;100 nanogram per milliliter (ng/mL) or transferrin saturation (TSAT) &lt;20%. IP treatment was allowed to continue during IV iron administration. Discontinuation of IV iron supplementation was recommended once the participant was no longer considered to be iron deficient (ferritin &gt;100 ng/mL and TSAT &gt;20%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-To-First Administration of RBC Transfusion as Rescue Therapy</measure>
    <time_frame>Baseline (Day 1, Week 0) up to EOS (4 weeks after the treatment period)</time_frame>
    <description>Time-to-first RBC transfusion as rescue therapy was calculated as (date of first occurrence of any RBC transfusion as rescue therapy, or date of censoring if no event had occurred) - (date of first dose of IP) + 1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2133</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.</description>
    <arm_group_label>Roxadustat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <description>Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Provision of Informed Consent prior to any study specific procedures

          2. Age ≥18 years at screening visit 1

          3. Previous versions of the protocol prior to US amendment ver 6.0 and outside of US
             amendment ver 7.0:

             Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native
             kidney end-stage renal disease (ESRD) at least 30 days prior to visit 1. Patients
             treated with hemodialysis must have access consisting of an arteriovenous fistula, AV
             graft, or tunneled (permanent) catheter. Patients on peritoneal dialysis must have a
             functioning peritoneal dialysis catheter in place.

             Starting with US amendment ver. 6.0 and outside of US amendment ver 7.0 (changed to
             recruit incident dialysis patients only):

             Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native
             kidney end-stage renal disease (ESRD) for a minimum of 2 weeks and a maximum of 4
             months prior to randomization. Patients treated with hemodialysis must have access
             consisting of an arteriovenous fistula, AV graft, or tunneled (permanent) catheter.
             Patients on peritoneal dialysis must have a functioning peritoneal dialysis catheter
             in place.

          4. Two central laboratory Hb values during the screening period, obtained at least 7 days
             apart, must be &lt;12 g/dL in patients currently treated with an erythropoietin analogue
             or &lt;10 g/dL in patients not currently treated with an erythropoietin analogue.
             Patients are considered not currently treated if they have not received either
             Mircera® for at least 8 weeks or any other erythropoietin analogue for at least 4
             weeks prior to visit 1.

          5. Ferritin ≥100 ng/mL at randomization (obtained from screening visit)

          6. TSAT ≥20% at randomization (obtained from screening visit)

          7. Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from
             screening visit)

          8. Serum vitamin B12 level ≥ LLN at randomization (obtained from screening visit)

          9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3x upper limit of
             normal (ULN), and total bilirubin (Tbili) ≤1.5 x ULN at randomization (obtained from
             screening visit)

         10. Body weight 45 to 160 kg (prescribed dry weight)

        Exclusion criteria:

          1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)

          2. Previous randomisation in the present study

          3. New York Heart Association Class III or IV congestive heart failure at enrolment

          4. Myocardial infarction, acute coronary syndrome, stroke, seizure or a
             thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism)
             within 12 weeks prior to randomization

          5. History of chronic liver disease (e.g., chronic infectious hepatitis, chronic
             auto-immune liver disease, cirrhosis or fibrosis of the liver)

          6. Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a
             history of pure red cell aplasia or other known causes for anemia other than CKD

          7. Known and untreated retinal vein occlusion or known and untreated proliferative
             diabetic retinopathy (risk for retinal vein thrombosis)

          8. Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV)
             of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan
             or MRI) conducted at screening or within 12 weeks prior to randomization.

          9. Uncontrolled hypertension at the time of randomization (defined as systolic BP ≥180
             mmHg or diastolic BP ≥100 mmHg on repeated measurement post-dialysis in hemodialysis
             patients or at any time in peritoneal dialysis patients), contraindication to epoetin
             alfa treatment (e.g., pure red cell aplasia, hypersensitivity or know inability to
             tolerate epoetin alfa)

         10. History of prostate cancer, breast cancer or any other malignancy, except the
             following: cancers determined to be cured or in remission for ≥5 years, curatively
             resected basal cell or squamous cell skin cancers, cervical cancer in situ or resected
             colonic polyps.

         11. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)

         12. Chronic inflammatory diseases such as rheumatoid arthritis, SLE, ankylosing
             spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to
             be the principal cause of anemia

         13. Known hemosiderosis, hemochromatosis or hypercoagulable condition

         14. Any prior organ transplant with the exception of an autologous renal transplant or a
             renal transplant that was subsequently removed (&quot;explanted&quot;) or scheduled organ
             transplantation date

         15. Any red blood cell (RBC) transfusion during the screening period

         16. Any current condition leading to active significant blood loss

         17. Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase
             inhibitor (HIF-PHI)

         18. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) or has participated in any other clinical study that included
             drug treatment within the month preceding the first administration of IP in this
             study. (Note: patients consented and screened, but not randomized in this study or a
             previous study are not excluded)

         19. History of alcohol or drug abuse within 2 years prior to randomization

         20. Females of childbearing potential, unless using contraception as detailed in the
             protocol or sexual abstinence (see Section 3.8)

         21. Pregnant or breastfeeding females

         22. Known allergy to the investigational product or any of its ingredients

         23. Any medical condition, including active, clinically significant infection, that in the
             opinion of the investigator or Sponsor may pose a safety risk to a patient in this
             study, which may confound efficacy or safety assessment, or may interfere with study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Fishbane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Houser, MD</last_name>
    <role>Study Director</role>
    <affiliation>AZ R&amp;D, Gaithersburg, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <zip>94534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sun Valley</city>
        <state>California</state>
        <zip>91352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lanham</city>
        <state>Maryland</state>
        <zip>20706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shawnee</city>
        <state>Oklahoma</state>
        <zip>74804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sterling</city>
        <state>Virginia</state>
        <zip>20164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bluefield</city>
        <state>West Virginia</state>
        <zip>24701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Launceston</city>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahan</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wahroonga</city>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Botevgrad</city>
        <zip>2140</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gotse Delchev</city>
        <zip>2900</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Razlog</city>
        <zip>2760</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samokov</city>
        <zip>2000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandanski</city>
        <zip>2800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silistra</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolyan</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <zip>V2C 2T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1P 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>190 61</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajka</city>
        <zip>8400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1077</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <zip>600006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ghaziabad NCR</city>
        <zip>201012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkatta</city>
        <zip>700027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucknow</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maharashtra</city>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mysore</city>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nadiad</city>
        <zip>387001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vijayawada</city>
        <zip>520 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20219</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veracruz</city>
        <zip>91900</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>L27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciechanów</city>
        <zip>06-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Końskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pszczyna</city>
        <zip>43-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwałki</city>
        <zip>16-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-758</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <zip>440034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kralovsky Chlmec</city>
        <zip>077 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 34</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granollers (Barcelona)</city>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Västerås</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Can Tho</city>
        <zip>900000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hochiminh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hue</city>
        <zip>530000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5740C00002&amp;amp;attachmentIdentifier=1cab3812-b878-4cc4-9c31-d56a8992967c&amp;amp;fileName=D5740C00002_redacted_CSP_from_PRS.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D5740C00002&amp;amp;attachmentIdentifier=4c981c0f-6734-4567-b362-92b2e86d7fdf&amp;amp;fileName=D5740C00002-SAP-ed4_Redacted_(1).pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>September 26, 2019</results_first_submitted>
  <results_first_submitted_qc>November 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2019</results_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal,</keyword>
  <keyword>CKD,</keyword>
  <keyword>Epoetin alfa,</keyword>
  <keyword>Roxadustat,</keyword>
  <keyword>dialysis,</keyword>
  <keyword>anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02174731/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 197 centers in 18 countries worldwide across the United States (US), Canada, Latin America, Australia, Asia and Europe between 01 July 2014 and 26 September 2018. Participants with chronic kidney disease (CKD) who were on dialysis were recruited in this study.</recruitment_details>
      <pre_assignment_details>Study had a screening period (up to 6 weeks), treatment period (up to 4 years) and follow-up period (4 weeks after treatment period for those who completed treatment). 2133 participants were randomized, of which 2106 were included in the analysis and 27 were excluded. Only participants included in the analysis are presented in the participant flow.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally three times a week (TIW) throughout the treatment period (up to 4 years). For hemodialysis (HD) participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain hemoglobin (Hb) values of 11±1 grams per deciliter (g/dL). Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa</title>
          <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) subcutaneous (SC) or intravenous (IV) injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 international unit per kilogram (IU/kg) TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1051"/>
                <participants group_id="P2" count="1055"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1048"/>
                <participants group_id="P2" count="1053"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="982"/>
                <participants group_id="P2" count="990"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participant decision</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment before randomization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intention-To-Treat (ITT) analysis set included all participants who were randomized to investigational product (IP) irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa</title>
          <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1051"/>
            <count group_id="B2" value="1055"/>
            <count group_id="B3" value="2106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="15.30"/>
                    <measurement group_id="B2" value="54.5" spread="14.97"/>
                    <measurement group_id="B3" value="54.0" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="429"/>
                    <measurement group_id="B3" value="855"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="625"/>
                    <measurement group_id="B2" value="626"/>
                    <measurement group_id="B3" value="1251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="539"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="783"/>
                    <measurement group_id="B2" value="784"/>
                    <measurement group_id="B3" value="1567"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="597"/>
                    <measurement group_id="B2" value="598"/>
                    <measurement group_id="B3" value="1195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black of African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52</title>
        <description>Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation Analysis of Covariance (ANCOVA). Baseline Hb was used as a covariate and treatment group, cardiovascular (CV) history, geographic region and dialysis duration as fixed effects. The adjusted least squares (LS) mean estimates of change from baseline during Week 28 to Week 52 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0), Week 28 to 52</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52</title>
          <description>Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation Analysis of Covariance (ANCOVA). Baseline Hb was used as a covariate and treatment group, cardiovascular (CV) history, geographic region and dialysis duration as fixed effects. The adjusted least squares (LS) mean estimates of change from baseline during Week 28 to Week 52 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1003"/>
                <count group_id="O2" value="1016"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.041"/>
                    <measurement group_id="O2" value="0.68" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of roxadustat versus epoetin alfa was declared if the lower bound of the 95% confidence interval (CI) of the difference between roxadustat and epoetin alfa exceeded -0.75. Non-inferiority p-value is 1-sided.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
            <estimate_desc>Difference between groups (roxadustat minus Epoetin alfa) in LS mean changes.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8‑Week Evaluation Period</title>
        <description>Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 36,without having received rescue therapy within 6 weeks prior to and during this 8 week evaluation period was analysed using Mixed Model of Repeated Measures (MMRM). Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 36 are presented for participants that did not receive rescue therapy within 6 weeks prior to and during this 8‑week evaluation period.</description>
        <time_frame>Baseline (Day 1, Week 0), Week 28 to 36</time_frame>
        <population>The Per Protocol Set (PPS) included all randomized participants without important protocol deviations who had received at least 8 weeks of study treatment and had valid corresponding Hb measurements. Participants from the PPS, with data available for analysis are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8‑Week Evaluation Period</title>
          <description>Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 36,without having received rescue therapy within 6 weeks prior to and during this 8 week evaluation period was analysed using Mixed Model of Repeated Measures (MMRM). Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 36 are presented for participants that did not receive rescue therapy within 6 weeks prior to and during this 8‑week evaluation period.</description>
          <population>The Per Protocol Set (PPS) included all randomized participants without important protocol deviations who had received at least 8 weeks of study treatment and had valid corresponding Hb measurements. Participants from the PPS, with data available for analysis are presented.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="836"/>
                <count group_id="O2" value="864"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.044"/>
                    <measurement group_id="O2" value="0.74" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of roxadustat versus epoetin alfa was declared if the lower bound of the 95% CI of the difference between roxadustat and epoetin alfa exceeded -0.75. Non-inferiority p-value is 1-sided.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>Difference between groups (roxadustat minus Epoetin alfa) in LS mean change.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Total Time of Hb Within the Interval of &gt;=10 g/dL From Week 28 to Week 52</title>
        <description>The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was &gt;=10 g/dL was computed and subsequently divided by the time between the measurements from Week 28 to Week 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.</description>
        <time_frame>Week 28 to 52</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Total Time of Hb Within the Interval of &gt;=10 g/dL From Week 28 to Week 52</title>
          <description>The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was &gt;=10 g/dL was computed and subsequently divided by the time between the measurements from Week 28 to Week 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
          <units>proportion of total time</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="896"/>
                <count group_id="O2" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.012"/>
                    <measurement group_id="O2" value="0.76" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of roxadustat versus epoetin alfa was declared if the lower bound of the 95% CI of the difference between roxadustat and epoetin alfa exceeded -0.15. Non-inferiority p-value is 1-sided.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>Difference between groups (roxadustat minus Epoetin alfa) in LS mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52</title>
        <description>The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was within 10-12 g/dL was computed and subsequently divided by the time between the measurement from Week 28 to 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.</description>
        <time_frame>Week 28 to 52</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52</title>
          <description>The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was within 10-12 g/dL was computed and subsequently divided by the time between the measurement from Week 28 to 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Participants without any Hb measurements from Week 28 were not included in the analysis.</population>
          <units>proportion of total time</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="896"/>
                <count group_id="O2" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.013"/>
                    <measurement group_id="O2" value="0.63" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of roxadustat versus epoetin alfa was declared if the lower bound of the 95% CI of the difference between roxadustat and epoetin alfa exceeded -0.15. Non-inferiority p-value is 1-sided.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>Difference between groups (roxadustat minus Epoetin alfa) in LS mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24</title>
        <description>Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analysed using ANCOVA. Baseline Hb and baseline LDL were used as covariates and treatment groups, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0) to Week 24</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24</title>
          <description>Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analysed using ANCOVA. Baseline Hb and baseline LDL were used as covariates and treatment groups, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>millimole per liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="902"/>
                <count group_id="O2" value="937"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.026"/>
                    <measurement group_id="O2" value="-0.05" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority was also declared as the lower bound of the 95% CI exceeded 0 and p-value was lower than 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
            <estimate_desc>Difference between groups (roxadustat minus Epoetin alfa) in LS mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)</title>
        <description>Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb is defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Changes in Hb from baseline to mean value during Weeks 28 to 52 in participants with baseline hsCRP &gt;ULN was analyzed using a MAR based multiple imputation ANCOVA. Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 52 are presented.</description>
        <time_frame>Baseline (Day 1, Week 0), Week 28 to 52</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Only participants who consented to the use of donated biomarker samples and had baseline hsCRP &gt;ULN were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)</title>
          <description>Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb is defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Changes in Hb from baseline to mean value during Weeks 28 to 52 in participants with baseline hsCRP &gt;ULN was analyzed using a MAR based multiple imputation ANCOVA. Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 52 are presented.</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis. Only participants who consented to the use of donated biomarker samples and had baseline hsCRP &gt;ULN were included in the analysis.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.077"/>
                    <measurement group_id="O2" value="0.59" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of roxadustat versus epoetin alfa was declared if the lower bound of the 95% CI of the difference between roxadustat and epoetin alfa exceeded -0.75. Non-inferiority p-value is 1-sided.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>MAR-based multiple imputation.</method_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
            <estimate_desc>Difference between groups (roxadustat minus Epoetin alfa) in LS mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)</title>
        <description>Oral iron supplementation was allowed for both treatment groups without restriction. Oral iron was recommended for dietary supplementation to support erythropoiesis and as the first line treatment for prevention and treatment of iron deficiency, unless the participant was intolerant to this route of treatment. In participants receiving roxadustat, the Investigator was allowed to initiate the use of an approved IV iron supplement if a participant's Hb value had not sufficiently responded to 2 or more dose increases of the IP, and ferritin &lt;100 nanogram per milliliter (ng/mL) or transferrin saturation (TSAT) &lt;20%. IP treatment was allowed to continue during IV iron administration. Discontinuation of IV iron supplementation was recommended once the participant was no longer considered to be iron deficient (ferritin &gt;100 ng/mL and TSAT &gt;20%).</description>
        <time_frame>Week 36 to EOS (4 weeks after the treatment period)</time_frame>
        <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)</title>
          <description>Oral iron supplementation was allowed for both treatment groups without restriction. Oral iron was recommended for dietary supplementation to support erythropoiesis and as the first line treatment for prevention and treatment of iron deficiency, unless the participant was intolerant to this route of treatment. In participants receiving roxadustat, the Investigator was allowed to initiate the use of an approved IV iron supplement if a participant's Hb value had not sufficiently responded to 2 or more dose increases of the IP, and ferritin &lt;100 nanogram per milliliter (ng/mL) or transferrin saturation (TSAT) &lt;20%. IP treatment was allowed to continue during IV iron administration. Discontinuation of IV iron supplementation was recommended once the participant was no longer considered to be iron deficient (ferritin &gt;100 ng/mL and TSAT &gt;20%).</description>
          <population>The ITT analysis set included all participants who were randomized to IP irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.</population>
          <units>milligram per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="885"/>
                <count group_id="O2" value="920"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.71" spread="236.12"/>
                    <measurement group_id="O2" value="91.37" spread="225.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-To-First Administration of RBC Transfusion as Rescue Therapy</title>
        <description>Time-to-first RBC transfusion as rescue therapy was calculated as (date of first occurrence of any RBC transfusion as rescue therapy, or date of censoring if no event had occurred) - (date of first dose of IP) + 1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
        <time_frame>Baseline (Day 1, Week 0) up to EOS (4 weeks after the treatment period)</time_frame>
        <population>The on-treatment+3 days safety analysis set included all participants who received at least 1 dose of randomized IP, except for those excluded from analysis. Participants were censored at 3 days after the last administration of the IP.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-To-First Administration of RBC Transfusion as Rescue Therapy</title>
          <description>Time-to-first RBC transfusion as rescue therapy was calculated as (date of first occurrence of any RBC transfusion as rescue therapy, or date of censoring if no event had occurred) - (date of first dose of IP) + 1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.</description>
          <population>The on-treatment+3 days safety analysis set included all participants who received at least 1 dose of randomized IP, except for those excluded from analysis. Participants were censored at 3 days after the last administration of the IP.</population>
          <units>events per 100 participant years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1048"/>
                <count group_id="O2" value="1053"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of roxadustat versus epoetin alfa was declared if the upper bound of the HR 95% CI of the difference between roxadustat and epoetin alfa was less than or equal to 1.8. Non-inferiority p-value is 1-sided. The CIs were from Wald and ties were calculated using the Efron method.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of IP administration (Day 1, Week 0) to 28 days after the last administration of the IP, with treatment duration up to 4 years.</time_frame>
      <desc>The on-treatment+28 days safety analysis set included all participants who received at least 1 dose of randomized IP, except for those excluded from analysis. Participants were censored at 28 days after the last administration of the IP. All-Cause Mortality represents all deaths due to any cause.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets orally TIW throughout the treatment period (up to 4 years). For HD participants, it was recommended that roxadustat was taken after completion of the HD session. For participants treated with an erythropoietin analogue at study entry, selection of initial roxadustat dose was based on the participant’s erythropoietin analogue dose at screening Visit 1. Participants not treated with an erythropoietin analogue at study entry initiated roxadustat using a tiered, weight-based dosing scheme. Doses were titrated to achieve and maintain Hb values of 11±1 g/dL. Dose adjustments were permitted starting at Week 4 and at intervals of every 4 weeks using a dose adjustment algorithm.</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa</title>
          <description>Participants received epoetin alfa (only use of Procrit®, Eprex® and Epogen® permitted in the study) SC or IV injection TIW, except for participants treated with epoetin alfa in a less frequent regimen prior to study entry. For participants treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was the actual dose administered at screening Visit 1. Participants treated with darbepoetin alfa or methoxy polyethylene glycol-epoetin beta prior to study entry initially received epoetin alfa at doses based on a conversion factor. For participants not treated with an erythropoietin analogue at study entry, the initial dose of epoetin alfa was 50 IU/kg TIW. Dose adjustments were to be consistent with local approved prescribing information.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="1048"/>
                <counts group_id="E2" subjects_affected="231" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="604" subjects_at_risk="1048"/>
                <counts group_id="E2" subjects_affected="606" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bone marrow reticulin fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hilar lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="49" subjects_affected="39" subjects_at_risk="1048"/>
                <counts group_id="E2" events="46" subjects_affected="41" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="1048"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="1048"/>
                <counts group_id="E2" events="43" subjects_affected="29" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1048"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pericarditis uraemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="1048"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Atrioventricular dissociation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="1048"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fibrous dysplasia of bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism tertiary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Oesophageal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="1048"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abdominal wall mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="1048"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intestinal metaplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pancreatic necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1048"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Complication of device insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="1048"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="1048"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1048"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dialysis membrane reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1048"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Clostridium bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="1048"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1048"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastroenteritis aeromonas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hiv infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatitis b</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Implant site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infected fistula</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Neurocysticercosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="1048"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Paraspinal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="1048"/>
                <counts group_id="E2" events="37" subjects_affected="24" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="80" subjects_affected="70" subjects_at_risk="1048"/>
                <counts group_id="E2" events="92" subjects_affected="78" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="40" subjects_at_risk="1048"/>
                <counts group_id="E2" events="46" subjects_affected="40" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1048"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Shunt infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tetanus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abscess of salivary gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Acute endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bacterial colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Balanoposthitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Campylobacter colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Candida pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Catheter site abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis c</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Citrobacter sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fungal peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Mycobacterium abscessus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Systemic viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1048"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular access site infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vulval cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemodialysis-induced symptom</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Post procedural urine leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular access malfunction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular access site thrombosis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="1048"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="46" subjects_affected="37" subjects_at_risk="1048"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Craniofacial fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Frostbite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Nerve root injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peritoneal dialysis complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular access site occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular access site pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Stress echocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Synovial fluid crystal present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Coagulation test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Echocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Human rhinovirus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulse absent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Respirovirus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Adult failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Calciphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="1048"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="55" subjects_affected="32" subjects_at_risk="1048"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="1048"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="1048"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Spinal ligament ossification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Calcification of muscle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteitis deformans</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>5q minus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Osteochondroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Skin angiosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1048"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1048"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Postresuscitation encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sciatic nerve neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tardive dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tonic convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vertigo cns origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="1048"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Illusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="1048"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Renal cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1048"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1048"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="1048"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="1048"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Red man syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Diabetic microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="1048"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="24" subjects_at_risk="1048"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="1048"/>
                <counts group_id="E2" events="33" subjects_affected="31" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1048"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Superior vena cava stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1048"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1048"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1048"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1048"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vascular compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Venous aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1048"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="391" subjects_at_risk="1048"/>
                <counts group_id="E2" subjects_affected="360" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="159" subjects_affected="114" subjects_at_risk="1048"/>
                <counts group_id="E2" events="153" subjects_affected="101" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="72" subjects_affected="61" subjects_at_risk="1048"/>
                <counts group_id="E2" events="94" subjects_affected="65" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="69" subjects_affected="60" subjects_at_risk="1048"/>
                <counts group_id="E2" events="64" subjects_affected="52" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="67" subjects_affected="43" subjects_at_risk="1048"/>
                <counts group_id="E2" events="95" subjects_affected="61" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="102" subjects_affected="70" subjects_at_risk="1048"/>
                <counts group_id="E2" events="77" subjects_affected="54" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="91" subjects_affected="79" subjects_at_risk="1048"/>
                <counts group_id="E2" events="85" subjects_affected="56" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="77" subjects_affected="61" subjects_at_risk="1048"/>
                <counts group_id="E2" events="76" subjects_affected="62" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="130" subjects_affected="85" subjects_at_risk="1048"/>
                <counts group_id="E2" events="124" subjects_affected="85" subjects_at_risk="1053"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="79" subjects_affected="64" subjects_at_risk="1048"/>
                <counts group_id="E2" events="83" subjects_affected="54" subjects_at_risk="1053"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>27 participants were excluded from the analysis due to Good Clinical Practice violations or system technical issues (17 in the roxadustat group and 10 in the epoetin alfa group).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Clinical Lead</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 302 885 1180</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

